EP2981821

MERCK SHARP & DOHME CORP.
Application Number
EP14778739A
Filing Date
Mar 31, 2014
Status
Patent Maintained As Amended
Oct 1, 2021
Grant Date
Nov 3, 2021
External Links
Slate, Register

Biblio Summary

The patent EP2981821B2 was granted on Nov 3, 2021 by Merck Sharp & Dohme Corp. The patent is currently Patent Maintained As Amended.

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

FORSYTHE, DOMINICSep 19, 2019ADMISSIBLE

The table below shows the patents of Merck Sharp & Dohme Corp. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3283882Blood-Based Biomarkers Of Tumor Sensitivity To Pd-1 AntagonistsOct 16, 20241
EP1841493Applicator For Inserting An ImplantMay 29, 20241
EP3265122Combination Of A Pd-1 Antagonist And Eribulin For Treating CancerMay 4, 20224

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.